RESEARCH TRIANGLE PARK, N.C., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the ...
MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a ...
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today ...
MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, Science 37, a leader in enhancing patient access to clinical trials, announced that it has received Frost & Sullivan’s 2024 Global Company ...
Science 37 has been tapped to use its virtual clinical trial tech for phase 3 trials of Synlogic’s treatment for the rare genetic metabolic disorder phenylketonuria (PKU). Under the deal, Science 37’s ...
New release sets the bar as the most comprehensive platform to orchestrate decentralized study conduct—unifying stakeholder journeys, increasing compliance, and generating the highest-quality data for ...
MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to clinical trials, today announced it has been named a finalist for two prestigious SCOPE ...
PLAYA VISTA, Calif.--(BUSINESS WIRE)--Science 37, a trailblazing company focused on “site-less” clinical trials, announced today the completion of a Phase 2b study for AOBiome, a clinical-stage life ...
“After an extensive review of opportunities available to Science 37, we believe that eMed provides the greatest value to our stockholders, customers, patients, and employees” said David Coman, Chief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results